H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...